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Abstract
Background: The combination of cytology and biopsies improves the recognition and typing of
small cell (SCLC) versus non small cell (NSCLC) lung cancers in the fiberoptic bronchoscopy
assessment of centrally located tumours.
Methods: We studied whether bronchial aspirates performed before biopsies (BA) and washings
performed after biopsies (BW) could increase the diagnostic yield of fiberoptic bronchoscopy. A
series of 334 consecutive samples taken in patients with suspicious fiberoptic bronchoscopy
findings was studied. Two hundred primary tumours were included in the study. The actual
diagnosis was based on surgical tissue specimen analysis and/or imaging techniques. The typing used
was that of the 1999 WHO/IASLC classification.
Results: The diagnosis of malignancy and tumour typing were analyzed according to the sequential
(combined) or single use of tests. Malignancy was assessed by cytology in 144/164 (87.8%) positive
biopsy cases and in 174/200 tumour cases (87.0%). BA before biopsies allowed 84.0% of cancers to
be diagnosed, whereas BW after biopsies allowed 79.0% of cancers to be found (p = ns). However,
combining biopsies with BW allowed 94.0% of cancers to be diagnosed, whereas 82.0% were
diagnosed by biopsies alone (p < 0.001). The highest diagnostic yield was obtained with the
combination of BA, biopsies and BW, with 97.0% sensitivity. Exact concordance in typing was
obtained in 83.8% of cases. The six surgically resected cases (3.0%) with negative cytology and
biopsy results included four squamous cell carcinomas with necrotizing or fibrous surface and two
adenocarcinomas, pT1 stage.
Conclusion: Fiberoptic bronchoscopy may reach a yield of close to 100% in the diagnosis and
typing of centrally located, primary lung cancers by combining bronchial aspirates, biopsies and
washings.
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Background
Lung cancer is the most common cause of cancer world-
wide, affecting about 200,000 men and women annually
in the United States and in Europe. Cigarette smoking has
been identified as the major risk factor of this type of can-
cer: 87 to 90% of all tracheal, bronchial and lung cancers
may be attributed to smoking [1]. Even at present, the
mortality rate of lung cancer remains over 85% at 5 years
[1,2]. In France, the incidence rose from 47.4 to 52.2 per
100,000 in men and from 3.7 to 8.6 per 10,000 in women
from 1980 to 2000 [3].
At time of diagnosis, about 90% of patients have symp-
toms related to local bronchopulmonary involvement,
invasion of adjacent structures or metastases, general
effects or paraneoplastic syndromes. After a chest radiog-
raphy is performed, fiberoptic bronchoscopy is the most
frequently used test [4], allowing the endobronchial
lesions to be mapped and sampled.
Appropriate treatment of lung tumours usually means
that the diagnosis is substantiated by biopsies and/or
brushing and washing specimens [1]. Though histopa-
thology remains the cornerstone of diagnosis, it is now
widely accepted that cytology may provide critical infor-
mation on the accurate typing of small cell (SCLC) versus
non small cell lung cancers (NSCLC) and that it may have
prognostic and therapeutic implications [5-8].
Bronchial washings, brushings and fine-needle aspira-
tions complement biopsies in the diagnosis of lung can-
cer, with overall sensitivity of 88% for centrally located,
endobronchial disease [9-11]. However the reliability of
cytology in the diagnosis of lung cancer is difficult to
assess, particularly when bronchial secretions are aspi-
rated. Bronchial aspirates and washings are often consid-
ered as a whole, with sensitivity values ranging between
50% and 90% [1]. Washings and brushings have an 80%
overall sensitivity but a low subtyping accuracy, especially
in the NSCLC components [12].
We have previously shown that provided specific require-
ments are followed, patients with centrally located lung
cancers are more likely to have positive cytology results
than positive biopsy results [7]. The data we obtained
were substantiated by fiberoptic bronchoscopy aspiration
of secretions, a type of material which is often discarded
because it is considered as yielding mainly degenerate
debris, mucus and inflammatory background [1,10].
To our knowledge, these results have not been duplicated.
One of the reasons is that diagnostic criteria, though well-
known in other types of samples, are difficult to analyze
in this kind of specimen: five slides per case are prepared
(56 cm2 screening area) and several tens of thousands of
cylindric cells, metaplastic elements and macrophages are
encountered [13]. Accordingly, the proportion of diag-
nostic cells may be very low and accurate diagnosis may
only be achieved by a screening procedure associating
cytotechnologists and cytopathologists.
A second step in our studies was to verify if sampling per-
formed before (BA) and after (BW) mucosal biopsies
could, as in other organs (brushings before and after
biopsy in the endoscopic diagnosis of gastroesophageal
malignancy) [14] allow better results to be obtained in the
search for cancer cells. We therefore studied whether a
combined approach could increase the diagnostic yield of
fiberoptic bronchoscopy in a series of 200 consecutive,
centrally located lung tumours.
Methods
Inclusion of cases
The study was approved by a local ethics committee. Over
a 7-year period, 855 patients underwent fiberoptic bron-
choscopy in the Departments of Internal Medicine and
Pulmonology of Lons-le-Saunier General Hospital,
France. Patients were referred by general practitioners
because of prolonged cough, chest pain, dyspnea or acute
symptoms of infection, or because of a haemoptysis epi-
sode. Patients had effusions or signs which could suggest
an invasion of adjacent structures or metastases in 127
cases (14.8%).
All patients were examined and questioned about their
smoking history, respiratory illnesses and symptoms, and
possible environmental or occupational exposure to car-
cinogens. All had chest radiography in posteroanterior
and lateral projections which were interpreted by a certi-
fied radiologist and by at least one pulmonologist.
Chest X-rays that showed no evidence of cancer were
recorded as "negative", even when other non cancerous
conditions (lobar emphysema, large bullae, diffuse
emphysema, benign patterns of calcification) may have
been present. Conversely, radiographic features such as
atelectasis, focal increased lung density, recurrent or
poorly resolving pneumonia associated or not with pleu-
ral reaction were recorded as suspicious.
Fiberoptic bronchoscopy was performed almost equally
by four pulmonologists (BD, DD, MP and BS). As summa-
rized in previous studies [9], the localisation and type of
mucosal abnormalities were separated into six categories:
1) tumor growth (vegetation or endobronchial mass), 2)
infiltration of the bronchial mucosa, 3) compression,
extrinsic or intrinsic, 4) necrosis, 5) non-specific findings
(localized redness of the mucosa, without swelling and
irregularity), and 6) normal appearance.CytoJournal 2007, 4:11 http://www.cytojournal.com/content/4/1/11
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After evaluation of both radiography and fiberoptic bron-
choscopy, only centrally located lesions (e.g. correspond-
ing to trachea and main bronchi) were selected for
analysis. Among the 855 patients, 557 (65.1%) had nega-
tive fiberoptic bronchoscopy, negative cytology and no
biopsy at first examination. 470 patients were not
reviewed. The 87 remaining patients (15.6%) were seen at
a later time during the 4-year period. All of them experi-
enced a new fiberoptic bronchoscopy examination.
Among them, 36/87 (41.4%) had suspicious chest X-ray
and positive fiberoptic bronchoscopy, and were included
in the series. Globally, 334 comparisons between cytology
and biopsy were obtained in centrally located bronchial
lesions, including 200 cancer cases.
Biopsy specimens
Biopsies were taken from abnormal areas of the bronchial
mucosa. Tissue specimens were fixed in Bouin's solution,
processed routinely for paraffin embedding and stained
with haematoxylin-eosin.
Examinations were performed by certified pathologists
using the 1999 WHO/IASLC classification [15]. Only
cases with unequivocal malignant features allowing
tumour typing were considered as positive.
Cytology specimens
Aspirates (BA) were obtained from the bronchial tree dur-
ing fiberoptic bronchoscopy before biopsies (mean vol-
ume = 30 ± 15,8 ml). Secretions were directly aspirated
through a flexible catheter inserted down the fiberoptic
bronchoscope. After biopsies have been performed, a
mean volume of 50 ml balanced saline solution was
instilled and re-aspirated (BW) in order to rince the
abnormal area.
Specimens were adequately separated and marked before
dispatch. The samples obtained were fixed in 50% ethanol
supplemented with 20 g/L polyglycol, PEG 1500 (Merck®
KgaA, VWR International, ref. 815005) and sent to the
cytopathology laboratory. Upon receipt, specimens were
centrifuged at 1500 RPM for 10 minutes. After the super-
natant has been discarded, the cell pellet was aspirated
and smeared on five Superfrost®  Plus slides (Menzel-
Gläser, Braunschweig, Germany) in order to allow suffi-
cient diagnostic accuracy [13]. After spray fixation (Cell-
Fixx®, Thermo Electron Corp. Waltham, MA), slides were
allowed to dessicate at room temperature for one hour.
Slides were then stained according to a hypochromic
Papanicolaou procedure.
Slides were screened by two certified cytotechnicians who
recognized and marked all cellular abnormalities on 4 of
the 5 slides. A single cytopathologist (EP) reviewed the
marked points and screened the last slide, thus allowing a
thorough examination of each sample.
When recognized, malignant cells were typed at high mag-
nification (x400) and recorded as follows: squamous-cell
carcinoma-type cells; adenocarcinomatous cells; large cell
carcinoma-type cells; SCLC-type cells; poorly differenti-
ated carcinomatous cells, none other specified; other cyto-
histologic type including sarcomas and lymphomas, if
applicable. However, from a practical point of view,
tumours were separated into SCLC and NSCLC cases
(Tables 1 and 2).
Recent studies have shown that there is no significant dif-
ference in survival rates between large cell neuroendocrine
carcinomas and SCLC when stratified by stage [15].
Accordingly, we did not perform specific search for neu-
roendocrine markers in cases of unequivocal NSCLC,
large cell carcinomas or typical SCLC.
Statistics
Data were coded and computerized. The Chi-square test
(standard or on paired series, when appropriate) was used
Table 1: Cross classification of combined bronchial aspirates and washings vs. biopsy results in 334 patients, including 200 lung cancer 
cases (%)
Biopsy
Us Neg. NSCLC SCLC Total
Aspirates
Neg. - 140* (84.3) 16 (11.9) 4 (13.3) 160 (47.9)
NSCLC 4 (ns) 24** (14.5) 116 (86.6) 2 (6.7) 146 (43.7)
SCLC - 2 (1.2) 2 (1.5) 24 (80.0) 28 (8.4)
Total 4 (1.2) 166 (49.7) 134 (40.1) 30 (9.0) 334 (100.0)
Us, unsatisfactory for evaluation; ns, not significant; Neg, negative; NSCLC, non small cell lung cancer; SCLC, small cell lung cancer
*including 6 cancer cases proven by CT scan findings, subsequently operated, and having squamous cell carcinoma with necrotizing or fibrous 
surface, pT1-2 stage (n = 4) or adenocarcinoma, pT1 stage (n = 2)
**including 4 squamous cell carcinomas in situ casesCytoJournal 2007, 4:11 http://www.cytojournal.com/content/4/1/11
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to compare categorical variables, and a probability level of
0.05 was regarded as significant.
Results
There were 334 combined cytology and biopsy samples
obtained in 288 men and 46 women (mean age = 65.0 ±
11.5 years). Cases were included until a total of 200 cases
with lung cancer were found. Tumours were confirmed by
subsequent surgical specimens (178 cases), or by a follow
up combining repeated CT scans, chest radiography and
clinical outcome when surgery was not possible (22
cases).
The patients included had abnormal chest X-rays in 314
cases. Some other, referred for hemoptysis had a normal
radiography (20 cases) but were also examined by
fiberoptic bronchoscopy, cytology and biopsies. The
fiberoptic bronchoscopy findings were as follows: tumour
growth in 238 cases (71.3%), infiltration in 73 cases
(21.9%) and non-specific findings in 14 cases (4.2%).
Fiberoptic bronchoscopy was normal in only 9 cases
(2.6%).
Comparison of cytological and biopsic results, taking into
account the cyto-histologic typing of tumors, is shown in
Table 1. Apart from one unsatisfactory biopsy, exact con-
cordance was obtained in 280 of 334 cases (83.8%). The
diagnosis of malignancy was assessed by cytology in 144
of 164 positive biopsy cases (87.8%) and in 174 of 200
tumour cases (87.0%). The false-negative rates of cytology
and biopsy used separately were 24.0% and 18.0% respec-
tively.
Comparative sensitivity values of 1) BA before biopsies, 2)
BW after biopsies, 3) biopsies alone, 4) combined aspi-
rates and 5) combined aspirates and biopsies together are
shown in Table 3. BA before biopsies allowed 84.0% of
cancers to be diagnosed, whereas BW after biopsies
allowed 79.0% of cancers to be found (χ2
ps = 1.64; p = ns).
However, combining biopsies to BW allowed 94.0% of
cancers to be diagnosed, whereas 82.0% were diagnosed
by biopsies alone (χ2
ps = 16.02; p < 0.001).
There was no significant difference in sensitivity between
biopsies + BA and biopsies + BW. The highest diagnostic
yield was obtained with the combination of BA, biopsies
and BW, with 97.0% sensitivity. Considering that biopsies
alone were positive in only 82.0% of cancer cases, there
was a 13.0%, 18.0% and 15.0% increase in sensitivity
when BA and BW were associated to biopsies, in compar-
Table 3: Results of bronchial aspirates (BA), biopsies and bronchial washings (BW) according to their combined or uncombined use in 
200 consecutive lung cancer cases
Us (%) Negative (% FN) Positive (% Se)
BA before biopsies 2 (1.0) 30 (15.0) 168 (84.0)
BW after biopsies 6 (3.0) 36 (18.0) 158 (79.0)
Haemorrhagic 5 (83.3) 23 (54.8) 127 (80.4)
Biopsies alone 4 (2.0) 32 (16.0) 164 (82.0)
Aspirates combined - 48 (24.0) 152 (76.0)
BA + biopsies - 16 (8.0) 184 (92.0)
Biopsies + BW 4 (2.0) 8 (4.0) 188 (94.0)
BA + biopsies + BW - 6 (3.0) 194 (97.0)
Us, unsatisfactory for evaluation
FN: false negative cases
Se: diagnostic sensitivity
Table 2: Differences between the three steps of the procedure in 
the 334 cases studied
BA Biopsies BW n Op.
Identical results (n = 264) Neg. Neg. Neg. 140 6§
NSCLC NSCLC NSCLC 104 104
SCLC SCLC SCLC 20 2
Globally concordant 
(n = 16)
Us NSCLC NSCLC 2 2
Neg. NSCLC NSCLC 2 2
Neg. SCLC SCLC 2 2
NSCLC NSCLC Us 2 2
NSCLC NSCLC Neg. 6 6
SCLC SCLC Neg. 2 2
Discordant cases (n = 54) Neg. NSCLC Neg. 16 16
Neg. SCLC Neg. 4 -
NSCLC Us Us 4 4
NSCLC Neg. Neg. 2 2
NSCLC Neg. NSCLC 22¶ 22
SCLC Neg. SCLC 2 2
NSCLC SCLC NSCLC 2* 2
SCLC NSCLC SCLC 2* 2
Total 334 178
BA, bronchial aspirates (before biopsies); BW, bronchial washings 
(after biopsies); Op., operated; Us, unsatisfactory for evaluation; Neg, 
negative; NSCLC, non small cell lung cancer; SCLC, small cell lung 
cancer
§cancer cases found by surgical biopsy and subsequently operated
¶including 4 squamous cell carcinomas in situ
*combined squamous cell/large cell and small-cell carcinomas were 
diagnosed on subsequent surgical specimens in 2 casesCytoJournal 2007, 4:11 http://www.cytojournal.com/content/4/1/11
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ison with 1) BA before biopsies, 2) BW after biopsies and
3) biopsies alone, respectively.
The six cancer cases (3.0%) with negative cytology and
biopsy results included 4 squamous cell carcinomas with
necrotizing or fibrous surface (fiberoptic bronchoscopy
showed a typical tumour growth) and 2 adenocarcino-
mas, pT1 stage (fiberoptic bronchoscopy showed a
mucosal infiltration in one case, and was subnormal in
the other).
Including unsatisfactory specimens, there remained 54
cases (16.2%) in which slightly discordant results could
be evidenced between cytology and biopsies (Table 2). In
all cases except four, there was agreement in cyto-histo-
logic typing. In two cases, a SCLC component was demon-
strated by cytology, whereas biopsies showed a large cell
carcinoma. These cases were considered as combined
small-cell/large cell carcinomas. In the two other cases, a
squamous cell carcinoma was evidenced by cytology,
whereas the biopsies demonstrated a SCLC. All initial dis-
cordances (small cell/large cell and squamous cell/SCLC)
were also evidenced by subsequent surgical specimens.
Discussion
According to the successive WHO classifications, and
from a therapeutic point of view, it is preferable to sepa-
rate lung tumours into SCLC that require intensive chem-
otherapy and sometimes radiation therapy, and NSCLC
that are preferably treated surgically. Tumours with com-
bined SCLC/large cell carcinoma components are fre-
quently encountered, particularly in large surgical
specimens [6]. It has been shown by the Pathology Com-
mittee of the International Association for the Study of
Lung Cancer (IASLC) that cytology combined with biop-
sies could improve the recognition of combined SCLC/
large cell lung carcinomas [6].
NSCLC cases represent about 80% of overall lung cancer
cases worldwide [1]. Cell typing may be difficult, particu-
larly on cytological and small biopsy samples, and the cri-
teria used are not always uniform.
For these reasons, it has been accepted that the terms
SCLC and NSCLC be used to report both biopsy and cytol-
ogy specimens in which the cell type can be identified, but
clear-cut morphological criteria are lacking [8,16,17].
Exact concordance in typing may exceed 80%, regardless
of the cytological method used (sputum, bronchial aspi-
rates, washings with isotonic saline and brushings)
[5,7,11]. In the present series, we evidenced two cases in
which a SCLC component was diagnosed by cytology and
a large cell carcinoma by biopsies.
Cytologic specimens collected from fiberoptic bronchos-
copy yield a higher rate of positive results than sputum,
particularly when considering washings and brushings.
Direct aspirates without washing are generally not consid-
ered as a valuable diagnostic material. However, the sen-
sitivity of secretions in diagnosing lung cancers has been
reported to be 81.0%, with no falsely positive results, and
can therefore match values obtained with washings [5].
In a previous study, we have demonstrated that an 88.3%
sensitivity value can be obtained, if one considers initial
biopsy results as the diagnostic reference, and 90.4% if
both histopathology and follow-up (considered as the
gold standard) are taken into account [7]. Data about
bronchial aspirates remain rare, mainly because authors
find it difficult to obtain representative material, thus
leading them to favour other cytological methods [4,16].
As shown previously, washings and brushings have rela-
tively high diagnostic yields (about 80%). However, nei-
ther adds significantly to the yield of biopsies [16].
Another limiting factor is the screening time of aspirates
and washings, which must be smeared on five slides per
specimen in order to reach a sufficient diagnostic sensitiv-
ity. Smearing accounts for a 56 cm2 screening area for each
specimen and a 15 to 45 min./sp. screening time, accord-
ing to the difficulties encountered [7].
Fiberoptic bronchoscopy and biopsies allow about 90%
of visible lung tumours to be diagnosed. However, biop-
sies cannot be performed in certain cases, particularly in
ambulatory patients with a haemorrhagic risk and in
patients with severe underlying diseases. Additionally,
there are cases where malignancy cannot be proven,
whereas fiberoptic bronchoscopy shows unquestionable
tumour growth. In such cases, the tumour surface is soft
and necrotic, or unusually hard and fibrous and may not
provide histologically identifiable material [16].
In the present study, performing both examinations (BA,
BW and biopsies) did not allow any unsatisfactory sample
to be obtained, reduced the false-negative rate of cytology
and significantly increased the diagnostic sensitivity of
tests versus biopsies alone. Washings performed after
biopsies (BW) were always found to be haemorrhagic. In
our experience however, blood did not prevent us from
recognizing and typing tumour cells.
Accordingly, we conclude that fiberoptic bronchoscopy
may reach a yield of close to 100% in the diagnosis and
typing of centrally located, primary lung cancers by com-
bining bronchial aspirates, biopsies and washings.CytoJournal 2007, 4:11 http://www.cytojournal.com/content/4/1/11
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